According to Altimmune's latest financial reports the company's current earnings (TTM) are -$88.45 M. In 2022 the company made an earning of -$84.91 M an increase over its 2021 earnings that were of -$97.1 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$88.45 M | 4.17% |
2022 | -$84.91 M | -12.55% |
2021 | -$97.1 M | 78.27% |
2020 | -$54.47 M | 164.65% |
2019 | -$20.58 M | -54.59% |
2018 | -$45.33 M | -12.95% |
2017 | -$52.07 M | -164.04% |
2016 | $81.3 M | -2506.1% |
2015 | -$3.38 M | -65.85% |
2014 | -$9.9 M | -15.12% |
2013 | -$11.66 M | 146.72% |
2012 | -$4.73 M | -16.07% |
2011 | -$5.63 M | -76.1% |
2010 | -$23.56 M | -8.89% |
2009 | -$25.86 M | 31.17% |
2008 | -$19.71 M | 549.91% |
2007 | -$3.04 M | 7.52% |
2006 | -$2.83 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | -$0.19 B | 108.39% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | -$18.95 M | -78.58% | ๐บ๐ธ USA |